跳到正文
原文
STAT 主站· Ed Silverman·· 2026-10-07AI 评分60

美国司法部发布白 collar 欺诈执法新指令,明确针对制药企业

STAT+: Justice Department targets drugmakers in new directive on combating white-collar fraud

AI 导读

美国司法部反欺诈部门上周发布新指令,明确将联邦《食品药品和化妆品法》纳入打击欺诈执法范围。该指令通常针对医疗机构和护理机构,此次扩展使药品和器械制造商正式成为执法重点。司法部前高管指出,此举是执法管辖权的显著扩展。

正文

By Ed Silverman

Oct. 7, 2026

Pharmalot Columnist, Senior Writer

Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter.

In a warning to life sciences companies, the U.S. Department of Justice last week issued a new directive for combating fraud that made a point of noting the agency will pursue violations of a federal law that tightly regulates the pharmaceutical industry.

Typically, the agency has pursued health fraud cases centered on providers, clinics, home health agencies, and hospices. By expressly including the Federal Food, Drug, and Cosmetic Act in the directive, the National Fraud Enforcement Division appears to be placing drug and device makers, among others, more clearly in its crosshairs.

“This is a subtle but significant expansion of their jurisdiction,” said Kevin Lowell, a member of the Miller & Chevalier law firm, who spent a decade at the DOJ, where he most recently had been a deputy chief in the National Fraud Enforcement Division’s health care fraud section.

STAT+ Exclusive Story

Already have an account? Log in

STAT+

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

来源:STAT 主站 · statnews.com